TY - JOUR
T1 - Association of chromosome 19 to lung cancer genotypes and phenotypes
AU - Wang, Xiangdong
AU - Zhang, Yong
AU - Nilsson, Carol L.
AU - Berven, Frode S.
AU - Andrén, Per E.
AU - Carlsohn, Elisabet
AU - Horvatovich, Peter
AU - Malm, Johan
AU - Fuentes, Manuel
AU - Végvári, Ákos
AU - Welinder, Charlotte
AU - Fehniger, Thomas E.
AU - Rezeli, Melinda
AU - Edula, Goutham
AU - Hober, Sophia
AU - Nishimura, Toshihide
AU - Marko-Varga, György
N1 - Funding Information:
The work was supported by Zhongshan Distinguished Professor Grant (XDW), The National Nature Science Foundation of China (91230204, 81270099, 81320108001, 81270131, 81300010), The Shanghai Committee of Science and Technology (12JC1402200, 12431900207, 11410708600, 14431905100), Operation funding of Shanghai Institute of Clinical Bioinformatics, and Ministry of Education, Academic Special Science and Research Foundation for PhD Education (20130071110043). MF is supported by grant FIS14/01538 (ISCIII- Fondos FEDER EU) and Proteomics Units at CIC belongs to ProteoRed-PRB2 (PT13-001, ISCIII, Fondos FEDER-EU)
Publisher Copyright:
© 2015, Springer Science+Business Media New York.
PY - 2015/6/1
Y1 - 2015/6/1
N2 - The Chromosome 19 Consortium, a part of the Chromosome-Centric Human Proteome Project (C-HPP, http://www.C-HPP.org), is tasked with the understanding chromosome 19 functions at the gene and protein levels, as well as their roles in lung oncogenesis. Comparative genomic hybridization (CGH) studies revealed chromosome aberration in lung cancer subtypes, including ADC, SCC, LCC, and SCLC. The most common abnormality is 19p loss and 19q gain. Sixty-four aberrant genes identified in previous genomic studies and their encoded protein functions were further validated in the neXtProt database (http://www.nextprot.org/). Among those, the loss of tumor suppressor genes STK11, MUM1, KISS1R (19p13.3), and BRG1 (19p13.13) is associated with lung oncogenesis or remote metastasis. Gene aberrations include translocation t(15, 19) (q13, p13.1) fusion oncogene BRD4-NUT, DNA repair genes (ERCC1, ERCC2, XRCC1), TGFβ1 pathway activation genes (TGFB1, LTBP4), Dyrk1B, and potential oncogenesis protector genes such as NFkB pathway inhibition genes (NFKBIB, PPP1R13L) and EGLN2. In conclusion, neXtProt is an effective resource for the validation of gene aberrations identified in genomic studies. It promises to enhance our understanding of lung cancer oncogenesis.
AB - The Chromosome 19 Consortium, a part of the Chromosome-Centric Human Proteome Project (C-HPP, http://www.C-HPP.org), is tasked with the understanding chromosome 19 functions at the gene and protein levels, as well as their roles in lung oncogenesis. Comparative genomic hybridization (CGH) studies revealed chromosome aberration in lung cancer subtypes, including ADC, SCC, LCC, and SCLC. The most common abnormality is 19p loss and 19q gain. Sixty-four aberrant genes identified in previous genomic studies and their encoded protein functions were further validated in the neXtProt database (http://www.nextprot.org/). Among those, the loss of tumor suppressor genes STK11, MUM1, KISS1R (19p13.3), and BRG1 (19p13.13) is associated with lung oncogenesis or remote metastasis. Gene aberrations include translocation t(15, 19) (q13, p13.1) fusion oncogene BRD4-NUT, DNA repair genes (ERCC1, ERCC2, XRCC1), TGFβ1 pathway activation genes (TGFB1, LTBP4), Dyrk1B, and potential oncogenesis protector genes such as NFkB pathway inhibition genes (NFKBIB, PPP1R13L) and EGLN2. In conclusion, neXtProt is an effective resource for the validation of gene aberrations identified in genomic studies. It promises to enhance our understanding of lung cancer oncogenesis.
KW - Antibodies
KW - Bioinformatics
KW - Genes
KW - Human disease
KW - Mass spectrometry
KW - Protein microarray
KW - Proteins
KW - mRNA
UR - http://www.scopus.com/inward/record.url?scp=84938417469&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84938417469&partnerID=8YFLogxK
U2 - 10.1007/s10555-015-9556-2
DO - 10.1007/s10555-015-9556-2
M3 - Article
C2 - 25982285
AN - SCOPUS:84938417469
VL - 34
SP - 217
EP - 226
JO - Cancer and Metastasis Reviews
JF - Cancer and Metastasis Reviews
SN - 0167-7659
IS - 2
ER -